Invivyd (IVVD) Gross Margin (2024 - 2025)
Invivyd (IVVD) posted Gross Margin of 93.37% for Q4 2025, up 1.81% on a QoQ basis from 91.71% in Q3 2025, and down 139.0% year-over-year from 239.42% in Q4 2024.
Invivyd (IVVD) Gross Margin (2024 - 2025) Analysis & Trends
Invivyd's Gross Margin history runs 2 years deep, the most recent figure standing at 93.37% for Q4 2025.
- Quarterly Gross Margin fell 139.0% year-over-year to 93.37% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 92.99% (down 64.0% YoY) and the FY2025 annual result came in at 92.99%, down 64.0% from the prior year.
- Gross Margin was 93.37% for Q4 2025 at Invivyd, up from 91.71% in the prior quarter.
- Across five years, Gross Margin topped out at 96.11% in Q2 2024 and bottomed at 91.33% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 88.95% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | 93.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 93.37% |
| Sep 30, 2025 | 91.71% |
| Jun 30, 2025 | 94.19% |
| Mar 31, 2025 | 92.62% |
| Dec 31, 2024 | 94.76% |
| Sep 30, 2024 | 91.33% |
| Jun 30, 2024 | 96.11% |